Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Road, Zhejiang, Hangzhou, 310003, China.
The Key Laboratory of Developmental Genes and Human Disease, Institute of Life Sciences, Southeast University, Nanjing, Jiangsu, 210096, China.
J Exp Clin Cancer Res. 2018 Feb 20;37(1):33. doi: 10.1186/s13046-018-0707-5.
Non-small-cell lung cancer (NSCLC) is currently the leading cause of cancer-related death. Accumulating evidences suggest that overcoming the therapeutic resistance in NSCLC is a big challenge. Recently, the outcomes of two independent phase 3 trials regarding Alectinib versus Crizotinib in ALK-positive NSCLC are encouraging. However, given the potential relevance of HGF-MET signaling and especially autophagy to the war against ALK-positive NSCLC between Alectinib and Crizotinib, it's too early to reach a convincing conclusion. Therefore, to further improve the therapeutic efficacy of ALK-positive NSCLC, this commentary highlights the negligence in design of relevant clinical trials, emphasizes the importance of molecular characteristics investigation, and discusses the prospect of combination therapy.
非小细胞肺癌（NSCLC）是目前癌症相关死亡的主要原因。越来越多的证据表明，克服 NSCLC 的治疗耐药性是一个巨大的挑战。最近，两项关于 Alectinib 与 Crizotinib 在 ALK 阳性 NSCLC 中的疗效的独立 3 期临床试验结果令人鼓舞。然而，鉴于 HGF-MET 信号和自噬在 Alectinib 和 Crizotinib 对抗 ALK 阳性 NSCLC 中的潜在相关性，现在下结论还为时过早。因此，为了进一步提高 ALK 阳性 NSCLC 的治疗效果，本评论强调了相关临床试验设计中的疏忽，强调了分子特征研究的重要性，并探讨了联合治疗的前景。
